Novartis India

Novartis India buys Minipress brands from Pfizer for ₹1,250 crore

The company's board approved the transaction on Monday, following which Novartis India executed an asset purchase agreement and trademark assignment deeds with Pfizer Inc and Pfizer Products Inc

Novartis India to acquire Pfizer's 'Minipress' trademark for ₹1,250 crore

Novartis India Ltd on Monday announced that its Board of Directors has approved the acquisition of the trademarks 'Minipress' and 'Minipres' from Pfizer Inc. USA and Pfizer Products Inc. USA for a total consideration of approximately Rs 1,250 crore. In a regulatory filing, the company said the transaction involves the acquisition of the trademarks registered in India and certain related intellectual property rights for a total aggregate consideration of Rs 1,250 crore. The company has executed an asset purchase agreement and trademark assignment deeds with Pfizer Inc USA and Pfizer Products Inc USA, with the signing and closing of the transaction scheduled to occur simultaneously, as per the filing. The company noted that Minipress XL (containing prazosin) is primarily indicated in India for treating hypertension (high blood pressure) and managing the urinary symptoms of benign prostatic hyperplasia (BPH). The filing further highlighted that as per IQVIA MAT July 2026 data, Minipre

Innovative ecosystem will make India attractive: Judith Love & Amitabh Dube

Novartis doubles down on innovation in India, eyeing R&D, clinical trials and a stronger regulatory ecosystem while moving away from traditional generics

Novartis India eyes therapy-aligned acquisition, Tier 2-3 market push

Pharma company Novartis India Ltd (NIL) plans to pursue disciplined, therapy-aligned acquisitions and deepen its last-mile reach into Tier 2 and Tier 3 markets to drive its next phase of growth, according to the company's annual report. The company's future strategy focuses on five anchor therapy areas: pain management, wellness, women's health, neuroscience, and transplant immunology. It aims to build new avenues for growth by protecting and extending the equity of brands such as Voveran, Calcium Sandoz, Methergin, Tegrital, Myfortic, and Simulect. Vikas Gupta, Managing Director and Chief Executive Officer, Novartis India, stated that the company is focusing on deepening its reach into non-metro markets where its specialist franchises remain under-penetrated relative to their potential. This expansion is viewed as a direct lever for volume growth. For the FY 2026-27 transition, the company is bringing established franchises, including Voveran, Methergin, Macalvit, and Calcium Sando

ChrysCapital acquires Novartis India, appoints Vikas Gupta as CEO

The private equity firm has taken control of the BSE-listed drugmaker, appointed Vikas Gupta as CEO and plans to build a branded generics platform in India

Novartis brings India's first 'guided missile' therapy for prostate cancer

Novartis launches Pluvicto, a precision treatment that delivers radiation directly to cancer cells

MNCs, Indian drugmakers diverge to mutual gain: How win-win is it?

Novartis exits India's mass-market generics, signalling a deeper split between MNC innovation bets and domestic pharma scale

Novartis AG to exit listed India unit in $159 mn deal with ChrysCapital

Novartis AG will divest its entire stake in Novartis India to a ChrysCapital-led consortium for Rs 1,446 crore, triggering an open offer that could push the deal size to nearly Rs 2,000 crore

Novartis shares hit 20% upper circuit as Swiss parent to sell entire stake

Novartis AG has agreed to sell 17.4 million fully paid-up equity shares, representing 70.68 per cent equity of Novartis India, to a consortium

Novartis to sell majority stake in India unit in ₹1,446 crore deal

The consortium will offer ​Novartis India's ‌public shareholders ₹860.64 per share, ‌an exchange filing showed, representing a 3.6 per cent ‌premium to ​its closing ​price on Thursday

Ex-date alert! These 16 stocks go ex-dividend on July 22; are you eligible?

Here is the complete list of stocks that will trade ex-dividend on July 23, following their announcements of dividend rewards for shareholders

Novartis soars 11%; board to support parent firm explore strategic options

According to reports, Dr Reddy's Laboratories is likely in a race to acquire Novartis AG's stake in Novartis India.

Novartis announces strategic review of Novartis India Limited

Drug major Novartis AG on Friday announced a strategic review of Novartis India Ltd, a public company listed on the BSE. The strategic review will include an assessment of the 70.68 per cent shareholding of Novartis AG in the company, the drug firm said in a statement. Novartis India Ltd is separate from Novartis Healthcare Pvt Ltd, the wholly owned subsidiary of Novartis group in India. Novartis Healthcare Pvt Ltd includes the Novartis Corporate Centre in Hyderabad, the commercial arm of Novartis in India, and R&D teams, which currently conduct clinical trials at more than 300 trial sites in the country. The strategic review will not impact Novartis Healthcare Pvt Ltd, Novartis AG stated. There can be no assurance that the strategic review of Novartis India Ltd will be completed in 2024, or that the outcome would result in the implementation of any transaction, it said. Novartis remains deeply committed to India with a footprint that has expanded significantly in recent years, i

JB Pharma, Novartis ink Rs 1,089 cr deal for select ophthalmology brands

JB Chemicals & Pharmaceuticals Ltd (JB Pharma)on Tuesday said it has inked a trade mark licence agreement along with promotion and distribution pact with Novartis for select ophthalmology brands entailing a total sum of Rs 1,089 crore. The board of directors at its meeting held on December 19, 2023 approved the execution of a trade mark licence agreement with Novartis Innovative Therapies AG, which is perpetual in nature for the Indian market, for a portfolio of select ophthalmology brands which will be effective in January 2027, JB Pharma said in a regulatory filing. The board also approved the promotion and distribution agreement with Novartis Healthcare Pvt Ltd for the same portfolio of select ophthalmology brands for the Indian market for a period of three years starting December 2023, it added. On the financial details of the agreements, JB Pharma said it will pay USD 116 million (Rs 964 crore), excluding applicable taxes, stamp duty and working capital, for the trade marks ..

Drug firm Novartis reports 29% increase in net profit at Rs 23.68 cr

Drug firm Novartis India on Friday reported 29.04 per cent increase in net profit at Rs 23.68 crore for the second quarter ended September 30, 2023. The company had logged a net profit of Rs 18.35 crore in the year-ago period, according to a regulatory filing by Novartis India. However, revenue from operations was down 22.41 per cent at Rs 78.76 crore as against Rs 101.52 crore, it added. Total expense was at Rs 63.21 crore, down 27.4 per cent. Shares of Novartis India on Friday settled at Rs 684.50 apiece on BSE, up 6.06 per cent from the previous close.

Price war begins for Novartis cardiac drug as JB Pharma cuts rate by 50%

Novartis' blockbuster drug is set to lose patent in Jan; JB Pharma, one of the four marketers in India of generi versions, has slashed the price of its brand Azmarda to Rs 39.6 a tablet

Dr Reddy's Laboratories inks exclusive sales pact with Novartis India

Dr Reddy's Laboratories has entered into an exclusive sales and distribution agreement with Novartis India Ltd (NIL), a statement said

HDFC Bank, IndusInd in 'red flag' list on nearing foreign investment cap

A listed company enters the list when the available legroom for overseas investment is less than 3 per cent of the permissible limit

Novartis India Q1 net profit jumps over 5-fold to Rs 4.39 cr on price cuts

The company had posted a net profit of Rs 79 lakh in the corresponding period of previous fiscal

Top headlines: Govt to set up Rs 1-trn agri infra fund, job cuts at Zomato

Business Standard brings to you the top headlines of the day